Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions DisclosureBusiness Wire • 07/20/26
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&DBusiness Wire • 06/22/26
Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone AssayZacks Investment Research • 05/14/26
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing SolutionBusiness Wire • 05/13/26
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong ExecutionZacks Investment Research • 05/05/26
Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/05/26
RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D DataZacks Investment Research • 04/13/26
Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research WorkflowsBusiness Wire • 04/09/26
Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/10/26
Revvity, Inc. (RVTY) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/26
Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference TranscriptSeeking Alpha • 03/02/26